Company intelligence / Profile preview

Centillion Fund

Alnwick, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Centillion enables on-demand, GMP-compliant manufacture of mRNA and self-amplifying RNA (saRNA) via modular "Biofoundry-in-a-Box" technology. It supports rapid production and transition of RNA-based therapeutics from discovery to clinical trials, allowing up to 1 million doses in 24 hours at a single site[1].

Modalities: mRNA-based drugsRNA-based drugsSelf-amplifying RNALipid nanoparticle delivery therapy
Industry: Contract Manufacturing Organization

Partnerships

Quotient Sciences (first CDMO partner)[1]Wellcome Leap (program partner/funder)[1]

Beyond the preview

Go deeper on Centillion Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centillion Fund.

Explore the full profile